Effects of CYP2C19 Genetic Polymorphisms on the Pharmacokinetic and Pharmacodynamic Properties of Clopidogrel and Its Active Metabolite in Healthy Chinese Subjects-Reference-Cited by-同舟云学术

Effects of CYP2C19 Genetic Polymorphisms on the Pharmacokinetic and Pharmacodynamic Properties of Clopidogrel and Its Active Metabolite in Healthy Chinese Subjects

Published:2018-07 Issue:7 Volume:40 Page:1170-1178
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Song Bai-Li,Wan Meng,Tang Dan,Sun Chao,Zhu Yu-Bing,Linda Nyame,Fan Hong-Wei,Zou Jian-Jun

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference29 articles.

1. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery

2. Role of phenotypic and genetic testing in managing clopidogrel therapy;Chan;Blood,2014

3. High-dose clopidogrel versus ticagrelor for treatment of acute coronary syndromes after percutaneous coronary intervention in CYP2C19 intermediate or poor metabolizers: a prospective, randomized, open-label, single-centre trial;Zhang;Acta Cardiol,2016

4. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite;Kazui;Drug Metab Dispos,2010

5. Influence of CYP2C19 loss-of-function variants on the antiplatelet effects and cardiovascular events in clopidogrel-treated Chinese patients undergoing percutaneous coronary intervention;Zou;Eur J Clin Pharmacol,2013

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Temporal trends in use of antisecretory agents among patients administered clopidogrel‐based dual antiplatelet therapy after percutaneous coronary intervention;Pharmacoepidemiology and Drug Safety;2024-05-21

2. Integrating Clopidogrel’s First-Pass Effect in a Joint Semi-Physiological Population Pharmacokinetic Model of the Drug and Its Inactive Carboxylic Acid Metabolite;Pharmaceutics;2024-05-20

3. The Cytochrome P450 2C19 Polymorphism Associated with Major Adverse Cardiovascular Events Risk in Kazak Patients Undergoing Percutaneous Coronary Intervention and Receiving Clopidogrel;Endocrine, Metabolic & Immune Disorders - Drug Targets;2023-02

4. Antiplatelet Therapy Aims and Strategies in Asian Patients with Acute Coronary Syndrome or Stable Coronary Artery Disease;Journal of Clinical Medicine;2022-12-15

5. Temporal trends in use of antisecretory agents among patients administered clopidogrel- based dual antiplatelet therapy after percutaneous coronary intervention;2022-11-29